Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SUBLOCADE Clear all
Completed Phase 3 Interventional

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

NCT06023459
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions
Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone
Drug
Lead sponsor
Yih-Ing Hser
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Completed No phase listed Observational

Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care

NCT00471042
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions
Buprenorphine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Not applicable Interventional Results available

Virtual Empowered Relief for Chronic Pain

NCT05057988
View directory record Official record
Conditions
Chronic Pain, Pain
Interventions
Empowered Relief class
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 31, 2026, 7:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Maternal Brain Imaging in Opioid Use Disorder

NCT06008990
View directory record Official record
Conditions
Opioid Use Disorder, Substance-Related Disorders, Substance Use, Pregnancy Related, Narcotic-Related Disorders, Buprenorphine Dependence
Interventions
Buprenorphine, Maternal Brain MRI, Blood Samples, Questionnaires
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Combined Injectable Treatment for HIV and OUD

NCT05991622
View directory record Official record
Conditions
Human Immunodeficiency Virus, Opioid Use Disorder
Interventions
Combined LAI Treatment: Cabenuva and Sublocade
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Not applicable Interventional Results available

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

NCT04762537
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

NCT03235154
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 31, 2026, 7:48 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department

NCT07430345
View directory record Official record
Conditions
Fracture
Interventions
Buprenorphine 0.15 MG, Hydromorphone 0.25 mg IV
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Phase 3 Interventional Results available

Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

NCT02696096
View directory record Official record
Conditions
Opioid Addiction
Interventions
FMRI, Suboxone
Other · Drug
Lead sponsor
Butler Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

NCT04982627
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions
BNI Chatbot, OUD Education & Treatment Resources
Behavioral
Lead sponsor
Center for Progressive Recovery, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 31, 2026, 7:48 AM EDT
Withdrawn Phase 3 Interventional

Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)

NCT04455802
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Buprenorphine or Placebo, Morphine or Placebo
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Early Phase 1 Interventional Results available

Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine

NCT05076370
View directory record Official record
Conditions
Addiction
Interventions
CBD Day 1, CBD Day 2, CBD Day 3
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Phase 4 Interventional Results available

Starting Treatment With Agonist Replacement Therapies (START)

NCT00315341
View directory record Official record
Conditions
Opiate-related Disorders
Interventions
Buprenorphine/naloxone, Methadone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 31, 2026, 7:48 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

NCT06442566
View directory record Official record
Conditions
Opioid Withdrawal, Chronic Pain
Interventions
Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Phase 3 Interventional Results available

Dane County Drug Court Study for Addicted Offenders

NCT01843751
View directory record Official record
Conditions
Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 31, 2026, 7:48 AM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

NCT00320801
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
66
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Not applicable Interventional Results available

HEALing Communities Study

NCT04111939
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
Communities That HEAL, Wait-list control
Other
Lead sponsor
RTI International
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Lexington, Kentucky • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

NCT00000330
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 31, 2026, 7:48 AM EDT
Not listed Phase 4 Interventional

Integrating Buprenorphine Into HIV Treatment

NCT00241930
View directory record Official record
Conditions
Opiate Dependence, HIV Infections
Interventions
Integrating drug treatment into HIV services
Behavioral
Lead sponsor
Organization to Achieve Solutions in Substance Abuse (OASIS)
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Oakland, California • San Leandro, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2005 · Synced Oct 31, 2026, 7:48 AM EDT
Active, not recruiting Not applicable Interventional

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

NCT05288751
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Contingency Management
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Phase 2 Interventional

Effective Treatment for Prescription Opioid Abuse

NCT00719095
View directory record Official record
Conditions
Prescription Opioid Dependence
Interventions
buprenorphine taper followed by naltrexone maintenance, Behavioral therapy
Drug · Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Not applicable Interventional Results available

STAMPS: South Carolina Buprenorphine Treatment Initiation, Adherence, and Retention Utilizing Mobile Health Units and Peer Support Specialists

NCT06384781
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Peer Support Checklist
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Clinton, South Carolina • Seneca, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 7:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial

NCT00684554
View directory record Official record
Conditions
Opioid-Related Disorders, Heroin Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 31, 2026, 7:48 AM EDT